Divalproex Sodium Tablet, Extended Release
Product Images NDC 72789-286

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 72789-286). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)

Chemical structure of divalproex sodium showing the molecular arrangement with sodium ion (Na+) and two valproic acid molecules in the complex.*

FDA Label Image

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)

A cumulative percentage curve chart comparing the reduction in CPS rate for patients treated with Divalproex Sodium Delayed-Release tablets versus placebo. The vertical axis shows percent reduction in CPS rate from -100% to 100%, indicating worsening or improvement, while the horizontal axis shows the percent of patients from 0 to 100%. The Divalproex sodium line demonstrates greater improvement across a higher percentage of patients compared to placebo.*

FDA Label Image

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)

A cumulative distribution plot comparing the percentage reduction in complex partial seizures (CPS) rate among patients treated with high dose versus low dose divalproex sodium delayed release. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS rate, with improvements indicated upwards and worsening downwards.*

FDA Label Image

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)

A bar chart comparing the effects of Placebo and Divalproex Sodium Extended-Release Tablets. The y-axis shows a numerical scale from 0 to 1.2, with Placebo at 0.6 and Divalproex Sodium Extended-Release Tablets at 1.2. The chart includes a note indicating statistical significance with a p-value of 0.006.*

FDA Label Image

Image (9f0c730e 9756 4a9a 9277 B4ef5ca07604 201 1)

Divalproex sodium 250 mg extended release oral tablets carton from PD-Rx Pharmaceuticals, Inc. The packaging displays the product name, strength, dosage form, and labeler. The label features a black arrow-shaped design pointing downward on a white background.*

FDA Label Image

Image (1fc9a662 2c99 4c65 B31c Ebee40f357aa 232 1)

FDA Label Image

72789286 Label (72789286)

Label for Divalproex sodium extended-release tablets, 250 mg strength, containing 60 tablets. The label includes the NDC 72789-286-60 and is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. It also features dosage instructions, warnings about drowsiness, and storage instructions, along with lot number K22C87 and expiration date 04/2024.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.